ConductScience.org, home

Paper39474397

Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.

Wang YQ and 9 others. World J Gastroenterol, 2024. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. Papers, record 39474397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39474397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
PubMed
Journal
World J Gastroenterol
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
1.32, provisional
iCite
Revised in PubMed
2024-10-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang YQYu-Qin
2Pan DDi
3Yao ZYZhi-Yuan
4Li YQYu-Qi
5Qu PFPeng-Fei
6Wang RBRun-Bang
7Gu QHQing-Hao
8Jiang JJie
9Han ZXZheng-Xiang
10Liu HNHao-Nan

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Body Mass IndexMajor topic
Phenylurea CompoundsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
QuinolinesMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
Humans
Male
Female
Middle Aged
Retrospective Studies
Prognosis
Aged
Obesity
Neoplasm Staging
Adult
Treatment Outcome
Progression-Free Survival
Hepatitis B
Overweight

Source PubMed

Download CSV of topics

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
234880251Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma.Nat Commun2021https://conductscience.org/library/papers/34880251PubMed
337598406Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.Int J Surg2023https://conductscience.org/library/papers/37598406PubMed
429577028Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study.J Clin Transl Hepatol2018https://conductscience.org/library/papers/29577028PubMed
515199035Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.JAMA2004https://conductscience.org/library/papers/15199035PubMed
629972759Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.N Engl J Med2018https://conductscience.org/library/papers/29972759PubMed
731876896Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.JAMA Oncol2020https://conductscience.org/library/papers/31876896PubMed
828130846AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018https://conductscience.org/library/papers/28130846PubMed
929449192Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.Lancet Oncol2018https://conductscience.org/library/papers/29449192PubMed
1034976804The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study.Front Oncol2021https://conductscience.org/library/papers/34976804PubMed
1120207633Body fatness and bevacizumab-based therapy in metastatic colorectal cancer.Gut2010https://conductscience.org/library/papers/20207633PubMed
1215051297Appropriate BMI for Asian populations.Lancet2004https://conductscience.org/library/papers/15051297PubMed
1330882850The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy.JAMA2019https://conductscience.org/library/papers/30882850PubMed
1435982962Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.Front Oncol2022https://conductscience.org/library/papers/35982962PubMed
1520175765Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence.Aliment Pharmacol Ther2010https://conductscience.org/library/papers/20175765PubMed
1635379737Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.J Immunother Cancer2022https://conductscience.org/library/papers/35379737PubMed
1722446023Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies.Eur J Cancer2012https://conductscience.org/library/papers/22446023PubMed
1830273398Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.PLoS One2018https://conductscience.org/library/papers/30273398PubMed
1912365956Prevalence and trends in overweight among US children and adolescents, 1999-2000.JAMA2002https://conductscience.org/library/papers/12365956PubMed
2031069144Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.Oncoimmunology2019https://conductscience.org/library/papers/31069144PubMed

See all 37 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42882861Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Cancers (Basel)2026https://conductscience.org/library/papers/42882861PubMed
42851698Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42851698PubMed
41810107Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis.J Clin Transl Hepatol2026https://conductscience.org/library/papers/41810107PubMed
41675519Global, regional, and national burden of liver cancer attributable to high BMI, 1990-2021, with future projections to 2040.Front Oncol2025https://conductscience.org/library/papers/41675519PubMed
41546382Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.Oncologist2026https://conductscience.org/library/papers/41546382PubMed
41267926Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes.MedComm (2020)2025https://conductscience.org/library/papers/41267926PubMed
41236792Prognostic Impact of Body Mass index in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: An Updated Systematic Review and Meta-Analysis.Technol Cancer Res Treat2025https://conductscience.org/library/papers/41236792PubMed
40497086Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma.World J Gastroenterol2025https://conductscience.org/library/papers/40497086PubMed
40308633Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy.Front Nutr2025https://conductscience.org/library/papers/40308633PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39474397

GET https://conductscience.org/api/papers/v1/39474397/references?page=2